MedTrace Logo

Impact of Guidelines on Cardiovascular and Economic Outcomes With Focus on Lipid Lowering Drugs

NCT02929550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5304

Last updated 2020-11-25

No results posted yet for this study

Summary

Methods: All patients \<75 years registered in the Swedish Secondary Prevention after Heart Intensive care Admission registry (SEPHIA), will be followed-up within one year post-myocardia infarction (MI). The REACH risk prediction and a calibrated model for recurrent cardiovascular disease (CVD) events and death will be used to estimate base case, and calibrated CVD outcomes based on gender-specific risk factors. The predicted impact of the LDL-C reduction on the risk of CVD will be based on Cholesterol Treatment Trialists´ Collaboration findings.

Conditions

  • Acute Myocardial Infarction

Interventions

OTHER

Well-controlled

Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l

Sponsors & Collaborators

Principal Investigators

  • Gunilla Journath, PhD · Karolinska Institutet

Eligibility

Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-01-31
Completion
2016-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929550 on ClinicalTrials.gov